glp-1 oral receptor agonists are generating a great deal of excitement as a potential inflection point in diabetes and obesity care. Amid the enthusiasm, however, a quieter and clinically important issue is Oral GLP-1s: benefits beyond weight

More on support groups

Mixing mcg into a calculation that expects mg shifts the answer by 1000x a documented cause of users either taking a microscopic dose or a fatal-equivalent dose depending on which direction the unit error went

QR Codes Generate QR Codes for your digital content

Abbreviations AUD: Alcohol Use Disorder CI: Confidence Interval DPP-4: Dipeptidyl Peptidase-4 DPP-4i: Dipeptidyl Peptidase-4 Inhibitor EMA: European Medicines Agency FDA: Food and Drug Administration GABA: Gamma-Aminobutyric Acid GLP-1: Glucagon-Like Peptide-1 GLP-1RA: Glucagon-Like Peptide-1 Receptor Agonist HR: Hazard Ratio I: I-squared Statistic ICD-10: International Classification of Diseases, 10th Revision NAc: Nucleus Accumbens NOS: NewcastleOttawa Scale NR: Not Reported PEth: Phosphatidylethanol PICOS: Population, Intervention, Comparison, Outcomes, Study Design PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses PROSPERO: International Prospective Register of Systematic Reviews Q: Cochrans Q Statistic RCT: Randomized Controlled Trial REML: Restricted Maximum Likelihood RYGB: Roux-en-Y Gastric Bypass SD: Standard Deviation SE: Standard Error T2DM: Type 2 Diabetes Mellitus : Tau-squared VTA: Ventral Tegmental Area References Carvalho AF, Heilig M, Perez A, Probst C, Rehm J

Detecting Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis

PT-141 , or bremelanotide , is a peptide analog of -melanocytestimulating hormone (-MSH) that activates melanocortin receptors in the central nervous system